TCTai-Yu Chiu

Tai-Yu Chiu

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tai-Yu Chiu has a total of 44 co-authors. Here are the top co-authors by number of shared publications:

  • De-Ming Yang

    Department of Medical Research, Taipei Veterans General Hospital, Taipei, Taiwan, ROC

    4 shared publications
  • Chiung-Tong Chen

    Institute of Biotechnology and Pharmaceutical Research National Health Research Institutes 35053 Zhunan Miaoli County Taiwan

    3 shared publications
  • Lun Kelvin Tsou

    Institute of Biotechnology and Pharmaceutical Research, National Health Research Institutes, Zhunan, Miaoli County, 35053, Taiwan.

    3 shared publications
  • Fu-Jen Kao

    Institute of Biophotonics, School of Medical Technology and Engineering, National Yang-Ming University, Taipei, Taiwan, Republic of China

    2 shared publications
  • Hsiao-Chuan Teng

    Department of Medical Research and Education, Taipei Veterans General Hospital Taipei, Taiwan, Republic of China

    2 shared publications
  • Ping-Chun Huang

    Department of Medical Research and Education, Taipei Veterans General Hospital Taipei, Taiwan, Republic of China

    2 shared publications

Latest Publications

  • Open Access

    Development of an orally bioavailable covalent STING inhibitor

    by Guang-Hao Niu, Wan-Chi Hsiao, Po-Hsun Lee, Li-Guo Zheng, Yu-Shao Yang, Wei-Cheng Huang, Chih-Chien Hsieh, Tai-Yu Chiu, Jing-Ya Wang, Ching-Ping Chen, et al.

    Pharmacological inhibition of cGAS-STING-controlled innate immune pathway is an emerging therapeutic strategy for a myriad of inflammatory diseases, including autoimmune disease, ulcerative colitis, non-alcoholic fatty liver disease and aging-related neurodegeneration. Here we report GHN105 as an orally bioavailable covalent STING inhibitor. Late-stage diversification of the briarane-type diterpenoid excavatolide B allowed the installation of solubility-enhancing functional groups while enhancing its activity as a covalent STING inhibitor against multiple human STING variants, including the S154 variant responsible for a genetic autoimmune disease. Selectively engaging the membrane-proximal Cys91 residue of STING, GHN105 dose-dependently inhibited cGAS-STING signaling and type I interferon responses in cells and in vivo. Orally administered GHN105 exerted marked therapeutic efficacy and reversed key pathological features in a delayed-treatment acute colitis mouse model. Notably, we also showed that GHN105 covalently engaged STING in the colon tissues. Our study provided proof of concept that synthetic briarane analog GHN105 serves as a safe and orally active covalent STING inhibitor. With a growing number of chronic inflammatory diseases linked to aberrant STING activation, orally bioavailable STING inhibitors would benefit patients by lowering the infection risk from frequent injections while allowing long-term systemic administration.

  • Open Access

    Synthesis and Evaluation of Small Molecule Drug Conjugates Harnessing Thioester-Linked Maytansinoids

    by Chen-Fu Lo, Tai-Yu Chiu, Yu-Tzu Liu, Li-Rung Huang, Teng-Kuang Yeh, Kuan-Hsun Huang, Kuan-Liang Liu, Chia-Yu Hsu, Ming-Yu Fang, Yu-Chen Huang, et al.

    Ligand-targeting drug conjugates are a class of clinically validated biopharmaceutical drugs constructed by conjugating cytotoxic drugs with specific disease antigen targeting ligands through appropriate linkers. The integrated linker-drug motif embedded within such a system can prevent the premature release during systemic circulation, thereby allowing the targeting ligand to engage with the disease antigen and selective accumulation. We have designed and synthesized new thioester-linked maytansinoid conjugates. By performing in vitro cytotoxicity, targeting ligand binding assay, and in vivo pharmacokinetic studies, we investigated the utility of this new linker-drug moiety in the small molecule drug conjugate (SMDC) system. In particular, we conjugated the thioester-linked maytansinoids to the phosphatidylserine-targeting small molecule zinc dipicolylamine and showed that Zn8_DM1 induced tumor regression in the HCC1806 triple-negative breast cancer xenograft model. Moreover, in a spontaneous sorafenib-resistant liver cancer model, Zn8_DM1 exhibited potent antitumor growth efficacy. From quantitative mRNA analysis of Zn8_DM1 treated-tumor tissues, we observed the elevation of gene expressions associated with a “hot inflamed tumor” state. With the identification and validation of a plethora of cancer-associated antigens in the “omics” era, this work provided the insight that antibody- or small molecule-based targeting ligands can be conjugated similarly to generate new ligand-targeting drug conjugates.


  • Open Access

    Click Chemistry and Multicomponent Reaction for Linker Diversification of Zinc Dipicolylamine-Based Drug Conjugates

    by Ching-Hua Tsai, Tai-Yu Chiu, Chiung-Tong Chen, Chia-Yu Hsu, Ya-Ru Tsai, Teng-Kuang Yeh, Kuan-Hsun Huang, Lun Kelvin Tsou

    An efficient Ugi multicomponent reaction with strain promoted azide-alkyne cycloaddition protocol has been utilized in concert or independently to prepare a small family of bioactive zinc(II) dipicolylamine (ZnDPA)-based SN-38 conjugates. With sequential click chemistry coupling between the cytotoxic payload and phosphatidylserine-targeting ZnDPA ligand derived from structurally diverse carboxylic acids, aldehyde or ketones, and isocyanides, we demonstrated that this convergent synthetic strategy could furnish conjugates harnessing diversified linkers that exhibited different pharmacokinetic profiles in systemic circulation in vivo. Among the eight new conjugates, comparative studies on in vitro cytotoxicities, plasma stabilities, in vivo pharmacokinetic properties, and maximum tolerated doses were then carried out to identify a potent ZnDPA-based SN-38 conjugate that resulted in pancreatic cancer growth regression with an 80% reduction of cytotoxic payload used when compared to that of the marketed irinotecan. Our work provided the roadmap to construct a variety of theranostic agents in a similar manner for cancer treatment.


  • Open Access

    Live-Cell Dynamic Sensing of Cd2+ with a FRET-Based Indicator

    by Tai-Yu Chiu, Po-Hsun Chen, Cha-Ling Chang, De-Ming Yang

    Cd 2+ causes damages to several human tissues. Although the toxicological and carcinogenetic mechanisms of Cd 2+ have been previously established, some basic questions on this toxicant remain unclear. In this study, we constructed Met-cad 1.57, a new fluorescent resonance energy transfer (FRET)-based Cd 2+ indicator, which contains a portion of a Cd 2+ -binding protein (CadR) obtained from Pseudomonas putida as the Cd 2+ sensing key. We produced a human embryonic kidney cell line HEK-MCD157 which stably expresses the Met-cad 1.57 for further investigations. Both fluorescence spectroscopy and FRET microscopic ratio imaging were used to monitor the Cd 2+ concentration within the living HEK-MCD157 cells. The dissociation constant of Met-cad 1.57 was approximately 271 nM. The function of Ca 2+ channels as a potential Cd 2+ entry gateway was further confirmed in the HEK-MCD157 cells. The organelle-targeted property of the protein-based Cd 2+ indicator directly reveals the nucleus accumulation phenomena. In summary, a human kidney cell line that stably expresses the FRET-based Cd 2+ indicator Met-cad 1.57 was constructed for reliable and convenient investigations to determine the Cd 2+ concentration within living cells, including the identification of the entry pathway of Cd 2+ and sub-cellular sequestration.


  • Open Access

    Intracellular Pb2+ Content Monitoring Using a Protein-Based Pb2+ Indicator

    by Tai-Yu Chiu, De-Ming Yang

    Lead ion (Pb2+) is one of the most hazardous heavy metals to almost all life forms. The components of store-operated Ca2+ entry as a molecular gateway have been previously found to participate in the cytotoxic entry of Pb2+. However, the safe levels of intracellular Pb2+ hiding in blood Pb2+ levels are still not determined with full certainty. The present study aimed to construct protein-based Pb2+ indicators to help establish a reliable setting for the content monitoring of intracellular Pb2+. A series of Pb2+ indicators based on fluorescence resonance energy transfer, Met-leads, were developed. The Pb2+-binding protein PbrR (from Cupriavidus metallidurans CH34) was applied between the fluorescent protein pair ECFP(ΔC11) and cp173Venus. The spectral patterns and sensing ranges of all Met-leads were characterized in vitro. Among these constructs, Met-lead 1.59 had relatively high ion selectivity and broad dynamic range (3.3–5.7). Consequently, this Met-lead was adopted in the cellular Pb2+ biosensing. The intracellular Pb2+ content in human embryonic kidney cells was successfully monitored using Met-lead 1.59 under both short- and long-term treatments. The existence of intracellular Pb2+ can be significantly sensed using Met-lead 1.59 after 3 h 0.5μM (10 μg/dl) exposure, which is 200 times more improved than previous live-cell indicators. In summary, a new Pb2+ indicator, Met-lead 1.59, was successfully developed for advanced research on Pb2+ toxicology.


  • Visualization of the Orai1 Homodimer and the Functional Coupling of Orai1-STIM1 by Live-Cell Fluorescence Lifetime Imaging

    by Ping-Chun Huang, Tai-Yu Chiu, Li-Chun Wang, Hsiao-Chuan Teng, Fu-Jen Kao, De-Ming Yang

    The Orai1-STIM1 constructed store-operated Ca2+ channels (SOCs) have been found to exert several essential Ca2+ entry/signaling cascades, e.g., the generation of immune response in T lymphocytes. Although biochemical and novel imaging evidence appear to indicate that Orai1 and STIM1 interact with each other to achieve store-operated Ca2+ entry (SOCE), the detailed mechanism of functional SOCE in situ has yet to be fully understood. In this study, green fluorescence protein (EGFP as donor) targeted to either the N- or C-terminal of Orai1 (wild type or ▵1-90+▵267-301 double deletion type) and mOrange (as acceptor) tagged STIM1 were used to comprise a fluorescence resonance energy transfer (FRET) pair within living PC12 cells. The fluorescence lifetime map and histogram/distribution of each single cell, determined by one-photon excitation fluorescence lifetime imaging microscopy (FLIM), was used to visualize FRET and show the Orai1 homodimer and Orai1-STIM1 binding. Both the color-coded lifetime map and the distribution of EGFP-tagged Orai1 significantly changed after the administration of thapsigargin, the SOCE stimulating agent. The FRET efficiency from each experimental set was also calculated and compared using double exponential analysis. In summary, we show the detailed interactions Orai1-Orai1 and Orai1-STIM1 within intact living cells by using the FLIM-FRET technique.


  • Open Access

    Dominant Role of Orai1 with STIM1 on the Cytosolic Entry and Cytotoxicity of Lead Ions

    by Tai-Yu Chiu, Hsiao-Chuan Teng, Ping-Chun Huang, Fu-Jen Kao, De-Ming Yang

    Pb2+ ions cause severe damages to living cells. In particular, our previous study showed that the Orai-STIM1 (stromal interacting protein 1)–formed store-operated Ca2+ channels (SOCs) allow Pb2+ entry. In relation to this, the present study investigates the molecular gating mechanism of Pb2+ entry by Orai1 with STIM1, as well as the resulting cytotoxicity on human embryonic kidney HEK293 cells. The store-operated Ca2+ entry (SOCE, activity of SOCs) and Pb2+ entry were measured using the fura-2 imaging method and indo-1 quenching strategy, as well as through an atomic absorption spectrophotometer. The results of RT-PCR, Western blot, fast confocal, and fluorescent lifetime imaging microscopy indicated the endogenous expression of Orai1 and STIM1 in HEK cells and the functional interaction between these two proteins during SOCE. Both SOCE and Pb2+ entry largely increased when Orai1 and STIM1 were overexpressed (3- and 1.64-folds, respectively) compared with nonfluorescent cells, and they were significantly attenuated when the E106Q mutation of Orail with STIM1 was cotransfected (6- and 2.25-folds decrease, respectively) compared with Orai1-STIM1 coexpressed cells. The ion gating for Pb2+ could be governed by the E106 region of Orai1. After sorting and subsequent cultures, the Orai1-STIM1 positive expressed cells behaved more sensitively to Pb2+ than the Orai1-STIM1 negative cells. In summary, the data suggest that Orai1, together with STIM1, plays a critical role in Pb2+ entry and the toxicity of Pb2+.